MHRA approves inavolisib for the treatment of breast cancer
Julian Beach, Interim Executive Director of Healthcare Quality and Access at the MHRA, said: “The approval of inavolisib provides a new targeted treatment for people with advanced breast cancer that has returned or spread after hormone therapy. Inavolisib can help delay the progression of the disease, giving patients more time with effective treatment. As with all licensed medicines, we will continue to monitor its safety and effectiveness closely as it becomes more widely used.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.